Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A small-molecule PI3Kα activator for cardioprotection and neuroregeneration.

Autor: Gong GQ; Cell Signalling, Cancer Institute, University College London, London, UK., Bilanges B; Cell Signalling, Cancer Institute, University College London, London, UK., Allsop B; Drug Discovery Group, Translational Research Office, University College London, London, UK., Masson GR; Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.; Division of Cellular Medicine, School of Medicine, University of Dundee, Dundee, UK., Roberton V; UCL Centre for Nerve Engineering, UCL School of Pharmacy, University College London, London, UK., Askwith T; Drug Discovery Group, Translational Research Office, University College London, London, UK., Oxenford S; Drug Discovery Group, Translational Research Office, University College London, London, UK., Madsen RR; Cell Signalling, Cancer Institute, University College London, London, UK., Conduit SE; Cell Signalling, Cancer Institute, University College London, London, UK., Bellini D; Medical Research Council Laboratory of Molecular Biology, Cambridge, UK., Fitzek M; Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Alderley Park, Macclesfield, UK., Collier M; Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Alderley Park, Macclesfield, UK., Najam O; The Hatter Cardiovascular Institute, University College London, London, UK., He Z; The Hatter Cardiovascular Institute, University College London, London, UK., Wahab B; Medicines Discovery Institute, School of Biosciences, Cardiff University, Cardiff, UK., McLaughlin SH; Medical Research Council Laboratory of Molecular Biology, Cambridge, UK., Chan AWE; Wolfson Institute for Biomedical Research, University College London, London, UK., Feierberg I; Molecular AI, Discovery Sciences, R&D, AstraZeneca, Waltham, MA, USA., Madin A; Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Morelli D; Cell Signalling, Cancer Institute, University College London, London, UK., Bhamra A; Proteomics Research Translational Technology Platform, Cancer Institute, University College London, London, UK., Vinciauskaite V; Division of Cellular Medicine, School of Medicine, University of Dundee, Dundee, UK., Anderson KE; Signalling Programme, Babraham Institute, Cambridge, UK., Surinova S; Proteomics Research Translational Technology Platform, Cancer Institute, University College London, London, UK., Pinotsis N; Institute of Structural and Molecular Biology, Birkbeck College, London, UK., Lopez-Guadamillas E; Cell Signalling, Cancer Institute, University College London, London, UK., Wilcox M; UCL Centre for Nerve Engineering, UCL School of Pharmacy, University College London, London, UK., Hooper A; Drug Discovery Group, Translational Research Office, University College London, London, UK., Patel C; Drug Discovery Group, Translational Research Office, University College London, London, UK., Whitehead MA; Cell Signalling, Cancer Institute, University College London, London, UK., Bunney TD; Institute of Structural and Molecular Biology, Division of Biosciences, University College London, London, UK., Stephens LR; Signalling Programme, Babraham Institute, Cambridge, UK., Hawkins PT; Signalling Programme, Babraham Institute, Cambridge, UK., Katan M; Institute of Structural and Molecular Biology, Division of Biosciences, University College London, London, UK., Yellon DM; The Hatter Cardiovascular Institute, University College London, London, UK., Davidson SM; The Hatter Cardiovascular Institute, University College London, London, UK., Smith DM; Emerging Innovations, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Phillips JB; UCL Centre for Nerve Engineering, UCL School of Pharmacy, University College London, London, UK., Angell R; Drug Discovery Group, Translational Research Office, University College London, London, UK.; Medicines Discovery Institute, School of Biosciences, Cardiff University, Cardiff, UK., Williams RL; Medical Research Council Laboratory of Molecular Biology, Cambridge, UK., Vanhaesebroeck B; Cell Signalling, Cancer Institute, University College London, London, UK. bart.vanh@ucl.ac.uk.

Publikováno v: Nature [Nature] 2023 Jun; Vol. 618 (7963), pp. 159-168. Date of Electronic Publication: 2023 May 24.

The Geometry of Visibles

Autor: Angell, R. B.

Publikováno v: Noûs, 1974 May 01. 8(2), 87-117.

Externí odkaz: https://www.jstor.org/stable/2214780

Evasion of a Human Cytomegalovirus Entry Inhibitor with Potent Cysteine Reactivity Is Concomitant with the Utilization of a Heparan Sulfate Proteoglycan-Independent Route of Entry

Autor: Oxenford Sj, Bonilla-Medrano Ni, Lee Ql, Matthew B. Reeves, Daniel P. Depledge, Angell R, Matthew J Murray

Publikováno v: Journal of Virology

Human cytomegalovirus (HCMV) is major pathogen of nonimmunocompetent individuals that remains in need of new therapeutic options. Here, we identify a potent antiviral compound (4,4′-diisothiocyano-2,2′-stilbenedisulfonic acid [DIDS]), its mechani

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::098a132913b2f65a08a66ba7dbb719e4
https://doi.org/10.1128/jvi.02012-19